John-Paul Jimenez
Overview
Explore the profile of John-Paul Jimenez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
344
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Proia D, Smith D, Zhang J, Jimenez J, Sang J, Ogawa L, et al.
Mol Cancer Ther
. 2015 Aug;
14(11):2422-32.
PMID: 26271675
The clinical benefits of chemotherapy are commonly offset by insufficient drug exposures, narrow safety margins, and/or systemic toxicities. Over recent decades, a number of conjugate-based targeting approaches designed to overcome...
2.
Smith D, Acquaviva J, Sequeira M, Jimenez J, Zhang C, Sang J, et al.
Target Oncol
. 2014 Aug;
10(2):235-45.
PMID: 25077897
Small molecule inhibitors of epidermal growth factor receptor (EGFR) tyrosine kinase activity, such as erlotinib and gefitinib, revolutionized therapy for non-small cell lung cancer (NSCLC) patients whose tumors harbor activating...
3.
Acquaviva J, He S, Zhang C, Jimenez J, Nagai M, Sang J, et al.
Mol Cancer Res
. 2014 May;
12(7):1042-54.
PMID: 24784839
Unlabelled: Activating mutations and/or overexpression of FGFR3 are common in bladder cancer, making FGFR3 an attractive therapeutic target in this disease. In addition, FGFR3 gene rearrangements have recently been described...
4.
Acquaviva J, Smith D, Jimenez J, Zhang C, Sequeira M, He S, et al.
Mol Cancer Ther
. 2014 Jan;
13(2):353-63.
PMID: 24398428
Activating BRAF kinase mutations serve as oncogenic drivers in over half of all melanomas, a feature that has been exploited in the development of new molecularly targeted approaches to treat...
5.
Proia D, Zhang C, Sequeira M, Jimenez J, He S, Spector N, et al.
Clin Cancer Res
. 2013 Nov;
20(2):413-24.
PMID: 24173541
Purpose: Treatment options for patients with triple-negative breast cancer (TNBC) are largely limited to systemic chemotherapies, which have shown disappointing efficacy in the metastatic setting. Here, we undertook a comprehensive...
6.
Sang J, Acquaviva J, Friedland J, Smith D, Sequeira M, Zhang C, et al.
Cancer Discov
. 2013 Mar;
3(4):430-43.
PMID: 23533265
Unlabelled: EML4-ALK gene rearrangements define a unique subset of patients with non-small cell lung carcinoma (NSCLC), and the clinical success of the anaplastic lymphoma kinase (ALK) inhibitor crizotinib in this...
7.
Shimamura T, Perera S, Foley K, Sang J, Rodig S, Inoue T, et al.
Clin Cancer Res
. 2012 Jul;
18(18):4973-85.
PMID: 22806877
Purpose: We describe the anticancer activity of ganetespib, a novel non-geldanamycin heat shock protein 90 (HSP90) inhibitor, in non-small cell lung cancer (NSCLC) models. Experimental Design: The activity of ganetespib...